The changes in malaria treatment policy were supported by evidence from molecular epidemiological resistance surveillance against SP [7], mainly P. falciparum dihydrofolate reductase (Pfdhfr) and dihydropteroate synthetase (Pfdhps) enzymes mutations [8, 9]. This evidence concerns the gene DHFR and malaria.